14 hours ago
March 19, 2026
- Excipient GMP-compliant manufacturing site in Clear Lake, Texas strengthens regional supply chain resilience and responsiveness for pharmaceutical customers across North America and Latin America
- First Clariant facility in the United States to manufacture pharmaceutical-grade polyethylene glycol excipients for oral and topical applications
- Strategic expansion reinforces Clariant's commitment to the North American pharmaceutical market and positions the company as a long-term partner
CHARLOTTE, NC, March 19, 2026 – Clariant is expanding its Clear Lake site to include excipient GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients. This expansion significantly improves availability and reliability for North American customers, while extending Clariant’s reach to Latin America. The multi-phase project addresses critical industry priorities such as supply chain security, continuity, and responsiveness, underscoring Clariant’s long-term strategic commitment to the U.S. pharmaceutical market.
The Clear Lake facility marks Clariant’s first U.S. manufacturing site dedicated to producing pharmaceutical-grade PEG excipients, representing a key milestone in the company’s healthcare growth strategy. By establishing regional production capabilities, Clariant is building a more resilient and responsive supply chain infrastructure for pharmaceutical manufacturers across the region.
The Clear Lake facility enables Clariant to deliver operational benefits that directly support pharmaceutical customers’ production planning and business continuity. Regional manufacturing results in significantly shorter lead times, allowing customers to respond faster to market demands and reduce inventory carrying costs, while offering more competitive pricing. Enhanced supply continuity provides the predictability pharmaceutical manufacturers require for complex production schedules and regulatory compliance.
“This expansion strengthens our ability to provide reliable local supply and positions us as a true partner to the North American pharmaceutical industry,” said Vaios Barlas, Head of Health Care at Clariant. “Beyond increased manufacturing capacity, we are fundamentally transforming how we serve our customers by bringing production closer to their operations and fostering more responsive, collaborative relationships.”
The Clear Lake facility upgrade and operations are designed to meet the pharmaceutical industry’s most rigorous quality, safety, and regulatory standards. Excipient GMP compliance ensures all manufacturing processes align with international pharmaceutical excipient standards, providing customers with the documentation, traceability, and quality assurance required for regulated pharmaceutical production. Clariant’s pharmaceutical-grade PEGs are registered in relevant pharmacopoeias and have negligible toxicity profiles, making them suitable for a wide range of applications.
Note to Editors:
As a member of the Drug, Chemical & Associated Technologies Association (DCAT), Clariant will attend DCAT Week, a premier event that gathers key decision-makers and innovators from the global biopharmaceutical manufacturing value chain, spanning development, manufacturing, supply, and technology.
DCAT Week offers a valuable platform to strengthen existing partnerships, explore new collaborations, and engage in meaningful dialogue on trends and challenges shaping the industry. Clariant looks forward to connecting with peers and contributing to conversations that advance innovation, reliability, and excellence in biopharmaceutical manufacturing.
Meeting suite location: Benjamin Royal Sonesta, 125 E 50th St, New York, NY 10022 – Suite 1503
Find more information about the conference here.
